Cochrane Summaries

Trusted evidence. Informed decisions. Better health.

Bisphosphonate therapy for osteogenesis imperfecta

Dwan K, Phillipi CA, Steiner RD, Basel D
Published Online: 
23 July 2014

Osteogenesis imperfecta is also known as brittle bone disease. It is a genetic condition which can be passed on from a parent to child or occur in the child without any other family history. An affected person is at risk for frequent breaks of the long bones or collapse of the vertebral bones. There is no cure for osteogenesis imperfecta and treatment is mostly supportive. This review looked at trials studying one of the groups of medications known as bisphosphonates which are more typically used to treat osteoporosis. They are used in osteogenesis imperfecta to try and reduce the number of bone fractures in affected individuals.

We included 14 trials, and most of these did not show a major reduction in fractures in affected individuals when treated with bisphosphonates. Each trial independently showed significant improvements in bone mineral density after treatment with oral or intravenous bisphosphonates. Bone pain, growth and quality of life indicators were not reported in enough detail and the effects of this treatment need further investigation. The long-term effectiveness and safety of bisphosphates, as well as dose and duration of therapy, require extended evaluation.

This record should be cited as: 
Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD005088. DOI: 10.1002/14651858.CD005088.pub3
Assessed as up to date: 
17 July 2014